MeiraGTx Holdings plc

NASDAQ:MGTX

Biotechnology

Healthcare
$8.32 +5.08%

+$0.53 today

Market cap
$813.12M
Beta
1.26
P/E (TTM)
-7.4
EPS (TTM)
-$1.48
52W Low $6.07High $11.85

Volume 0.58M

Average 0.84M

MGTX Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

MeiraGTx Holdings plcNASDAQ: MGTX

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns negative

Q1 FY2026 gross profit was -$2.91M, compared with $548K a year earlier. Trailing-twelve-month gross profit was $73.09M. Over 3 fiscal years it compounded at +68.8% a year.

Context

  • Gross profit amounted to 94.0% of revenue in FY2025, up 65.5 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$2.91M or moves back toward the trailing-twelve-month quarterly average of $18.27M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.91M-103.9% QoQ
Last fiscal yearDec 2025
$76.55M+706.8% YoY
LTMMar 2026
$73.09M+682.6% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-631.6%——
1 year+706.8%——
3-year CAGR+68.8%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
76.55M USD
Year-over-year change
+706.8%
4-year CAGR
+19.4%

Gross Profit vs competitors

How MGTX compares with its peers on the latest reported figures

  • MGTX's LTM Mar 2026 gross profit of $73.09M is the 2nd highest of the 9 companies compared; the peer median is $2.17M.
  • Its year-over-year change of +682.6% is the highest of 8, against a peer median of +23.0%.
  • Gross profit amounts to 91.6% of revenue for MGTX, versus a peer median of 93.3%.
MGTX Competitors Peer median
Gross Profit for MGTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KRYSKrystal Biotech, Inc.LTM Jun 2026$411.14M +22.6%—93.3%
MGTXMeiraGTx Holdings plcLTM Mar 2026$73.09M +682.6%+68.8%91.6%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$14.48M +56.0%-0.6%98.0%
QUREuniQure N.V.LTM Mar 2026$13.42M +23.0%-48.1%74.1%
OCGNOcugen, Inc.LTM Mar 2026$4.47M -1.3%-6.6%100.0%
RGNXREGENXBIO Inc.LTM Mar 2026-$120K -100.1%+37.2%0.1%
SANASana Biotechnology, Inc.LTM Mar 2026-$2.39M ———
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-$10.98M +90.3%—12.4%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-$101.61M +44.5%+5.1%153.7%
Peer median (excluding MGTX) $2.17M+23.0%-0.6%93.3%

Competitors are the stored peer set for MGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue37.7M15.92M14.02M33.28M81.39M
Cost of Revenue00023.79M4.84M
Gross Profit37.7M15.92M14.02M9.49M76.55M
Gross Margin100.0%100.0%100.0%28.5%94.0%
Research & Development66.69M85.73M103.79M119.48M129.62M
Selling, General & Admin43.77M46.55M47.29M54.22M52.9M
Operating Expenses110.46M132.28M151.08M173.7M182.52M
Depreciation & Amortization7.87M8.6M13.73M12.83M12.61M
EBITDA(71.4M)(116.07M)(57.05M)(121.69M)(89.4M)
EBITDA Margin-189.4%-729.1%-407.0%-365.7%-109.8%
Operating Income(72.76M)(116.36M)(137.06M)(164.21M)(105.97M)
Operating Margin-193.0%-730.9%-977.8%-493.4%-130.2%
Interest Income212K777K2.27M4.15M1.82M
Interest Expense288K4.95M13.25M13.27M12.2M
Other Income / Expenses(6.8M)(13.26M)53.03M16.42M(8.23M)
Income Before Tax(79.56M)(129.62M)(84.03M)(147.79M)(114.2M)
Pre-Tax Margin-211.0%-814.2%-599.5%-444.1%-140.3%
Income Tax Expense00000
Net Income(79.56M)(129.62M)(84.03M)(147.79M)(114.2M)
Net Margin-211.0%-814.2%-599.5%-444.1%-140.3%
EPS (Basic)(1.80)(2.87)(1.49)(2.12)(1.42)
EPS (Diluted)(1.80)(2.87)(1.49)(2.12)(1.42)
Weighted Avg Shares44.14M45.18M56.49M69.82M80.43M
Weighted Avg Shares (Diluted)44.14M45.18M56.49M69.82M80.43M

MeiraGTx Holdings plc

NASDAQ:MGTX

Intrinsic Alpha fair value

Locked

Current Price

$8.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.